Prohance

(Gadoteridol)

PreclinicalSmall molecule

BBracco Diagnostics, Inc

Prohance is one of 90 small molecule programs targeting Multiple Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

GlioblastomaActive, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

GlioblastomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

160 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

58 2

Keytruda

Merck & Co.

Phase 3

24 3

Opdivo

Bristol-Myers Squibb

Phase 3

18 4

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Yervoy

11 6

Ceenu

AAzurity Pharmaceuticals

Phase 3

21 7

Antabuse

Teva

Phase 3

5 8

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Study completion

NCT04373564

Clinical

Trials by Indication[1]

Glioblastoma1 trial

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Completed·OOHSU Knight Cancer Institute·N/A·NCT02359097·29 enrolled

Magnetic Resonance Imaging (MRI)1 trial

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

Completed·BBracco Diagnostics, Inc·Phase 4·NCT01613417·229 enrolled

Contrast Agent1 trial

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Completed· Bayer logo

Bayer·Phase 3·NCT05915702·303 enrolled

Central Nervous System1 trial

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

Completed· Bayer logo

Bayer·Phase 3·NCT00709852·402 enrolled

Multiple Sclerosis1 trial

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed·UUniversity of Maryland, Baltimore··NCT03396822·24 enrolled

4 more indications

Glioma1 trial

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

Terminated·OOncoSynergy, Inc.·Phase 1·NCT04608812·7 enrolled

Contrast Enhancement in Magnetic Resonance Imaging1 trial

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Completed· Bayer logo

Bayer·Phase 3·NCT05915728·410 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis

Completed·UUniversity of Utah·Phase 1·NCT05357833·11 enrolled

Unspecified1 trial

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting·GGuerbet·Phase 4·NCT04373564·2,076 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 16, 1992

PROHANCE

NDA NDA020131

Oct 9, 2003

PROHANCE MULTIPACK

NDA NDA021489

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Gadoteridol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadoteridol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadoteridol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021489). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBracco Diagnostics, Inc

Prohance

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Glioblastoma1 trial

Magnetic Resonance Imaging (MRI)1 trial

Contrast Agent1 trial

Central Nervous System1 trial

Multiple Sclerosis1 trial

Glioma1 trial

Contrast Enhancement in Magnetic Resonance Imaging1 trial

Secondary Progressive Multiple Sclerosis1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News